0.00

100.00% -1.17

Ocuphire Pharma Inc (OCUP)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.17

Offen:

24-Stunden-Volumen:

Relative Volume:

0.00

Marktkapitalisierung:

$30.65M

Einnahmen:

$16.45M

Nettoeinkommen (Verlust:

$-14.11M

KGV:

0.00

EPS:

0.84

Netto-Cashflow:

$-11.46M

1W Leistung:

-100.00%

1M Leistung:

-100.00%

6M Leistung:

-100.00%

1J Leistung:

-100.00%

1-Tages-Spanne:

$0.00

1-Wochen-Bereich:

$0.00

52-Wochen-Spanne:

$0.00

$3.3994

Ocuphire Pharma Inc Stock (OCUP) Company Profile

Firmenname

Ocuphire Pharma Inc

Sektor

Healthcare (1205)

Branche

Biotechnology (682)

Telefon

248-681-9815

Adresse

37000 GRAND RIVER AVE., FARMINGTON HILLS

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

OCUP's Discussions on Twitter

Vergleichen Sie OCUP mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OCUP	0.00	30.65M	16.45M	-14.11M	-11.46M	0.84
VRTX	467.12	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	762.38	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	567.35	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.83	24.08B	3.30B	-501.07M	1.03B	11.54

Ocuphire Pharma Inc Aktie (OCUP) Neueste Nachrichten

Nov 16, 2024

FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright - Defense World

Nov 16, 2024

Nov 13, 2024

Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Nov 13, 2024

Oct 25, 2024

Ocuphire Shares Rise After Extended US Patent For Nyxol Eye Drops Secured - Marketscreener.com

Oct 23, 2024

Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL

Oct 23, 2024

Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance

Oct 23, 2024

OCUP stock touches 52-week low at $1.14 amid market challenges - Investing.com UK

Oct 23, 2024

Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo! Voices

Oct 23, 2024

Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire

Oct 23, 2024

Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 22, 2024

Ocuphire Pharma acquires Opus Genetics - MSN

Oct 22, 2024

Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini

Oct 22, 2024

Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com

Oct 22, 2024

Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, - openPR

Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail

Oct 16, 2024

Oct 10, 2024

Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR

Oct 10, 2024

Sep 30, 2024

Ocuphire reports positive phase 3 results for eye treatment RYZUMVI - Investing.com

Sep 30, 2024

Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times

Sep 30, 2024

Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com South Africa

Sep 30, 2024

Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire

Sep 30, 2024

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan

Sep 30, 2024

Sep 24, 2024

OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire

Sep 24, 2024

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Sep 24, 2024

OFS Credit to offer preferred stock in public offering - MSN

Sep 24, 2024

Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 24, 2024

Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World

Sep 24, 2024

Sep 23, 2024

Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada

Sep 23, 2024

Is OCGN’s price to cash per share ratio a concern for investors? - US Post News

Sep 23, 2024

Sep 21, 2024

Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World

Sep 21, 2024

Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World

Sep 21, 2024

Sep 20, 2024

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Sep 20, 2024

Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance

Sep 20, 2024

Sep 19, 2024

All the Doctor Odyssey guest stars we know so far - Hidden Remote

Sep 19, 2024

Sep 18, 2024

Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR

Sep 18, 2024

Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News

Sep 18, 2024

American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Sep 18, 2024

Sep 17, 2024

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE

Sep 17, 2024

Sep 07, 2024